Abstract
The period of clinical application of leflunomide (LF) has indicated that by and large the results of its use in the routine practice are comparable with those obtained during clinical trials. The drug provides a considerable improvement in about 50-55% of patients with rheumatoid arthritis (RA) and permits a long monitoring of the disease activity. The rate of adverse reactions (AR) in the use of LF is lower than that in the administration of essential anti-inflammatory drugs (EAID). In most cases, ARs offer no serious threat to a patient and require no drug discontinuation. The duration of LF therapy is largely determined by the severity of the disease in a specific patient and by the qualification of a physician. The application of the standard LF treatment regiment takes about 6 observational months to provide a valid evaluation of the effect of the drug. If its saturated dose is not given, this interval may be much longer. The use of LF in combination with methotrexate (MT) in the patients who have benefited from MT yields better results than continued MT monotherapy and causes no significant increase in the number of AR. In the routine practice, LF has also shown good results when used in combination with biologicals. The currently gained clinical experience with LF enables the latter to be recommended for wide application in any types of RA both as basic monotherapy and in combination with other EAIDs and biologicals.
Highlights
The period of clinical application of leflunomide (LF) has indicated that by and large the results of its use in the routine practice are comparable with those obtained during clinical trials
The drug provides a considerable improvement in about 50—55% of patients with rheumatoid arthritis (RA) and permits a long monitoring of the disease activity
Поэтому в последних рекомендациях по применению биологическими препаратами (БП) и небиологических болезньмодифицирующих препаратов Американской коллегии ревматологов (АКР) предлагает использовать ЛФ наряду с МТ в качестве препарата выбора у больных, которые ранее не получали базисных противовоспалительных препаратов (БПВП) [29]
Summary
The period of clinical application of leflunomide (LF) has indicated that by and large the results of its use in the routine practice are comparable with those obtained during clinical trials. Martin и соавт., которые изучали результаты применения ЛФ у 116 больных РА, наблюдавшихся в ревматологическом центре Бордо, в течение первого года лечения препарат был отменен в 70% случаев [5]. Которые зафиксировали высокую частоту отмен в течение первого года лечения, отмечают, что больные в их группе были гораздо тяжелее, чем те, которых включали в рандомизированные клинические испытания ЛФ [8].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
